NSE seeks clarification on Q4 FY26 results compliance

Regulatory & Legal

BALAXI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+3.0%1-day move

₹22.61

prior close

₹22.90

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.4+0.5+0.4+0.4+3.0+4.2+6.1+6.1+7.0+6.1+5.4+8.3——

Up moveDown movePending

AI summary

NSE has asked Balaxi Pharmaceuticals to clarify certain aspects of its financial results for the quarter ended 31 March 2026 under SEBI Listing Regulations. The company's response is awaited. No specific issue or penalty has been disclosed yet, and the exchange is yet to receive the company's reply.

Likely market impact

Routine compliance query; minor concern. Watch for company's response, which could clarify any financial reporting issues.